Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 34 studies | 39% ± 16% | |
capillary endothelial cell | 15 studies | 30% ± 10% | |
endothelial cell of artery | 13 studies | 47% ± 18% | |
vein endothelial cell | 13 studies | 45% ± 11% | |
endothelial cell of vascular tree | 13 studies | 34% ± 13% | |
astrocyte | 9 studies | 31% ± 12% | |
retinal cone cell | 4 studies | 23% ± 7% | |
fibroblast | 4 studies | 18% ± 2% | |
oligodendrocyte precursor cell | 4 studies | 30% ± 9% | |
glutamatergic neuron | 3 studies | 31% ± 10% | |
microglial cell | 3 studies | 22% ± 3% | |
connective tissue cell | 3 studies | 21% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 2398.64 | 2630 / 2642 | 100% | 95.78 | 702 / 705 |
prostate | 98% | 1919.01 | 241 / 245 | 95% | 9.44 | 475 / 502 |
breast | 100% | 3495.45 | 459 / 459 | 88% | 9.50 | 983 / 1118 |
thymus | 99% | 2163.02 | 648 / 653 | 88% | 9.87 | 535 / 605 |
adrenal gland | 99% | 2590.43 | 255 / 258 | 83% | 13.96 | 190 / 230 |
lung | 99% | 2882.82 | 574 / 578 | 68% | 5.02 | 786 / 1155 |
ovary | 100% | 2652.17 | 180 / 180 | 41% | 3.07 | 177 / 430 |
uterus | 100% | 4027.44 | 170 / 170 | 36% | 4.04 | 167 / 459 |
esophagus | 91% | 3034.10 | 1313 / 1445 | 44% | 3.61 | 81 / 183 |
intestine | 99% | 2715.03 | 954 / 966 | 32% | 2.44 | 171 / 527 |
bladder | 100% | 2220.81 | 21 / 21 | 31% | 2.01 | 156 / 504 |
stomach | 80% | 1616.29 | 286 / 359 | 47% | 4.40 | 133 / 286 |
kidney | 62% | 741.45 | 55 / 89 | 60% | 7.43 | 541 / 901 |
pancreas | 15% | 111.46 | 49 / 328 | 85% | 8.57 | 152 / 178 |
adipose | 100% | 3871.48 | 1202 / 1204 | 0% | 0 | 0 / 0 |
heart | 100% | 2248.52 | 858 / 861 | 0% | 0 | 0 / 0 |
skin | 63% | 681.92 | 1147 / 1809 | 33% | 2.55 | 154 / 472 |
blood vessel | 88% | 1416.47 | 1177 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 69% | 3.14 | 20 / 29 |
muscle | 53% | 436.84 | 429 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 47% | 2.51 | 21 / 45 |
liver | 4% | 21.81 | 9 / 226 | 29% | 1.68 | 118 / 406 |
peripheral blood | 5% | 42.77 | 49 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 0.25 | 4 / 80 |
spleen | 3% | 19.39 | 8 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045123 | Biological process | cellular extravasation |
GO_0031642 | Biological process | negative regulation of myelination |
GO_2000403 | Biological process | positive regulation of lymphocyte migration |
GO_0097241 | Biological process | hematopoietic stem cell migration to bone marrow |
GO_0035633 | Biological process | maintenance of blood-brain barrier |
GO_0050901 | Biological process | leukocyte tethering or rolling |
GO_0071593 | Biological process | lymphocyte aggregation |
GO_0007520 | Biological process | myoblast fusion |
GO_0098609 | Biological process | cell-cell adhesion |
GO_0007286 | Biological process | spermatid development |
GO_0007159 | Biological process | leukocyte cell-cell adhesion |
GO_0070160 | Cellular component | tight junction |
GO_0005886 | Cellular component | plasma membrane |
GO_0036477 | Cellular component | somatodendritic compartment |
GO_0044291 | Cellular component | cell-cell contact zone |
GO_0009986 | Cellular component | cell surface |
GO_0098636 | Cellular component | protein complex involved in cell adhesion |
GO_0005923 | Cellular component | bicellular tight junction |
GO_0005178 | Molecular function | integrin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | JAM2 |
Protein name | Junctional adhesion molecule B (JAM-B) (Junctional adhesion molecule 2) (JAM-2) (Vascular endothelial junction-associated molecule) (VE-JAM) (CD antigen CD322) Junctional adhesion molecule 2 |
Synonyms | UNQ219/PRO245 VEJAM C21orf43 |
Description | FUNCTION: Junctional adhesion protein that mediates heterotypic cell-cell interactions with its cognate receptor JAM3 to regulate different cellular processes . Plays a role in homing and mobilization of hematopoietic stem and progenitor cells within the bone marrow . At the surface of bone marrow stromal cells, it contributes to the retention of the hematopoietic stem and progenitor cells expressing JAM3 . Plays a central role in leukocytes extravasation by facilitating not only transmigration but also tethering and rolling of leukocytes along the endothelium . Tethering and rolling of leukocytes are dependent on the binding by JAM2 of the integrin alpha-4/beta-1 . Plays a role in spermatogenesis where JAM2 and JAM3, which are respectively expressed by Sertoli and germ cells, mediate an interaction between both cell types and play an essential role in the anchorage of germ cells onto Sertoli cells and the assembly of cell polarity complexes during spermatid differentiation (By similarity). Also functions as an inhibitory somatodendritic cue that prevents the myelination of non-axonal parts of neurons (By similarity). During myogenesis, it is involved in myocyte fusion (By similarity). May also play a role in angiogenesis (By similarity). . |
Accessions | ENST00000312957.9 [P57087-2] ENST00000480456.6 [P57087-1] ENST00000460679.5 P57087 ENST00000400532.5 [P57087-3] H0YEX9 |